Trident Texofab Ltd Financials
Company Logo

Trident Texofab Ltd Financial Statement

Trident Texofab Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue29.21
Operating Expense26.72
Net Profit1.00
Net Profit Margin3.42
Earning Per Share1.00
EBIDTA2.94
Effective Tax Rate16.06
Invest in Trident Texofab Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Trident Texofab Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual99.48
Operating Expenses Annual93.33
Operating Profit Annual6.85
Interest Annual4.04
Depreciation1.52
Net Profit Annual1.08
Tax Annual0.09

Trident Texofab Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.06
Cash Flow from Operations2.71
Cash Flow from Investing-0.57
Cash Flow from Financing-2.05
Cash Flow at the End0.16

Trident Texofab Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)8.33
PBIT Margin (%)6.67
PBT Margin (%)5.51
Net PROFIT Margin (%)1.09
Return On Networth / Equity (%)5.47
Return On Networth /Employed (%)11.75
Return On Assets (%)1.91
Total Debt / Equity (X)2.48
Asset Turnover Ratio (%)1.76

Trident Texofab Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual21.73
Total Current Assets Annual52.10
Non Current Assets Annual29.79
Total Shareholders Funds Annual16.26
Total Assets Annual81.90

Trident Texofab Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 23, 2024, Trident Texofab Ltd has a market capitalization of 49.16 Cr. Value Research classifies it as a Micro-Cap company.
No, Trident Texofab Ltd is not debt-free with a debt-to-equity ratio of 2.47.
In FY 2023 , Trident Texofab Ltd recorded a total revenue of approximately 99.48 Cr marking a significant milestone in the company's financial performance.
Trident Texofab Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.1% and 0.1% annually, respectively..
Trident Texofab Ltd's current PE ratio is 45.52.
Trident Texofab Ltd's ROCE averaged 9.2% from the FY ending March 2022 to 2024, with a median of 8.4%. It peaked at 11.7% in March 2023, reflecting strong capital efficiency over the period..
Trident Texofab Ltd's latest EBIT is Rs. 5.21 Cr, surpassing the average EBIT of Rs. 5.25 Cr over the 5 years..